Sponsor: Regeneron
Sponsor Study ID: R3767-ONC-1613
Study Title: A Phase 1, Open Label, Dose Escalation and Cohort Expansion First in Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti LAG 3 mAb) Administered Alone or in Combination with REGN2810 (anti PD 1 mAb) in Patients with Advanced Malignancies
CTO #: 102602
NCT Number: NCT03005782
Phase: I
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Anus; Bladder; Bones and Joints; Brain and Nervous System; Breast; Cervix Uteri; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Hodgkin's Lymphoma; Ill-Defined Sites; Kaposi's Sarcoma; Kidney; Larynx; Leukemia, other; Lip, Oral Cavity and Pharynx; Liver; Lung; Lymphoid Leukemia; Melanoma, Skin; Multiple Myeloma; Mycosis Fungoides; Myeloid and Monocytic Leukemia; Non-Hodgkin's Lymphoma; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Hematopoietic; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Unknown Sites
Study Objectives: To evaluate safety and PK in order to determine an RP2D of REGN3767 as monotherapy and in combination with REGN2810 in patients with advanced malignancies, including lymphoma. To assess preliminary anti-tumor activity of REGN3767 alone and in combination with REGN2810 (separately by cohort) as measured by ORR.